Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 10/20 | 0.49 |
| ▸ | KDR | P35968 | 9/20 | 0.49 |
| ▸ | HCK | P08631 | 9/20 | 0.49 |
| ▸ | SRC | P12931 | 8/20 | 0.49 |
| ▸ | HTR6 | P50406 | 5/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | NPM1 | P06748 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182019 | 0.89 | LCK (0.56) | LCKKDRHCKSRCALK | |
| SCHEMBL4177451 | 0.87 | LCK (0.56) | LCKKDRHCKSRCHTR6 | |
| SCHEMBL4170462 | 0.87 | LCK (0.65) | LCKKDRHCKSRCABL1 | |
| SCHEMBL4167899 | 0.86 | LCK (0.66) | LCKKDRHCKSRC | |
| SCHEMBL4175044 | 0.85 | LCK (0.55) | LCKKDRHCKSRCALK | |
| SCHEMBL4175240 | 0.82 | LCK (0.56) | LCKKDRHCKSRCABL1 | |
| SCHEMBL4171677 | 0.82 | LCK (0.68) | LCKKDRHCKSRCABL1 | |
| SCHEMBL4181996 | 0.81 | LCK (0.75) | LCKKDRHCKSRCABL1 | |
| SCHEMBL4183618 | 0.80 | LCK (0.75) | LCKKDRHCKSRCABL1 | |
| SCHEMBL4185042 | 0.80 | LCK (0.47) | LCKKDRHCKSRCALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | claimed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | claimed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | claimed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | claimed |
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | disclosed |
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | SIVASANKARAN RAJEEV | 2009-03-12 | — | — | US | disclosed |
| EP-1993552-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007103432-A9 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007103432-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2007-09-13 | — | — | WO | disclosed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | EPHA5, EPHA7, EPHA1 | LCK 524/4885KDR 780/4885HCK 718/4885 |
| US-20050222171-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | LCK 30/4885KDR 1240/4885HCK 68/4885 |
| US-20090099167-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | LCK 30/4885KDR 1240/4885HCK 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.